2022
DOI: 10.1093/jjco/hyac073
|View full text |Cite|
|
Sign up to set email alerts
|

Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years

Abstract: Objective Many clinical trials for older patients with metastatic colorectal cancer have been conducted, and fluoropyrimidine and bevacizumab are standard treatments. However, the relationship between age and the efficacy and safety of this treatment is unclear in older metastatic colorectal cancer patients. Methods Individual data from two phase II studies on older (≥75 years), non-frail patients with metastatic colorectal c… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 31 publications
0
1
0
Order By: Relevance
“…Moriwaki et al [7] enrolled 102 nonfrail patients with metastatic colorectal cancer, with a median age of 80 years and receiving fluoropyrimidine as well as bevacizumab. Interestingly, chronological age was not associated with progression-free or overall survival.…”
Section: Chronological Age and Clinical Outcomesmentioning
confidence: 99%
“…Moriwaki et al [7] enrolled 102 nonfrail patients with metastatic colorectal cancer, with a median age of 80 years and receiving fluoropyrimidine as well as bevacizumab. Interestingly, chronological age was not associated with progression-free or overall survival.…”
Section: Chronological Age and Clinical Outcomesmentioning
confidence: 99%